Additive effect of multiple high-risk coronary artery segments on patient outcomes: LRP Study sub-analysis.

[1]  M. Budoff,et al.  Distribution of Coronary Artery Calcium by Age, Sex, and Race Among Patients 30-45 Years Old. , 2022, Journal of the American College of Cardiology.

[2]  L. Räber,et al.  Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. , 2022, JAMA.

[3]  Brian C. Case,et al.  Impact of baseline imaging of non-culprit coronary lesions and adverse events: Insight from LRP study. , 2021, Cardiovascular revascularization medicine : including molecular interventions.

[4]  R. D. de Winter,et al.  Non-culprit MACE-rate in LRP: The influence of optimal medical therapy using DAPT and statins. , 2021, Cardiovascular revascularization medicine : including molecular interventions.

[5]  ShengOlivia R. Liu,et al.  Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study , 2021, The Lancet.

[6]  F. Prati,et al.  Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. , 2021, Cardiovascular diagnosis and therapy.

[7]  Sean M. O'Brien,et al.  Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. , 2020, Circulation.

[8]  Ulf J Jensen,et al.  Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. , 2020, Journal of the American College of Cardiology.

[9]  Sean M. O'Brien,et al.  Initial Invasive or Conservative Strategy for Stable Coronary Disease. , 2020, The New England journal of medicine.

[10]  T. Ishimitsu,et al.  Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. , 2020, Journal of cardiology.

[11]  Habib Samady,et al.  Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study , 2019, The Lancet.

[12]  P. Serruys,et al.  Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up , 2018, European heart journal.

[13]  J. Ware,et al.  The Lipid-Rich Plaque Study of vulnerable plaques and vulnerable patients: Study design and rationale. , 2017, American heart journal.

[14]  Evelyn Regar,et al.  In vivo detection of high-risk coronary plaques by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-IVUS study. , 2014, European heart journal.

[15]  Samin K. Sharma,et al.  Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). , 2013, Journal of the American College of Cardiology.

[16]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[17]  Patrick W Serruys,et al.  Imaging of coronary atherosclerosis: intravascular ultrasound. , 2010, European heart journal.

[18]  J. Guyton,et al.  Development of the lipid-rich core in human atherosclerosis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.